References
- 1Piña-Garza JE, James KC.
14 – Movement Disorders . In: Piña-Garza JE, James KC (eds.), Fenichel’s Clinical Pediatric Neurology (Eighth Edition). Philadelphia: Elsevier; 2019. 278–95. DOI: 10.1016/B978-0-323-48528-9.00014-5 - 2Misulis KE, Samuels MA, Kirshner HS.
Chapter 5.7 – Movement Disorders . In: Zimmerman EE, Samuels MA, Kirshner HS, Misulis KE (eds.), Neurologic Localization and Diagnosis. New Delhi: Elsevier; 2023: 225–30. DOI: 10.1016/B978-0-323-81280-1.00036-6 - 3Zesiewicz TA, Sullivan KL, Hauser RA. Chorea induced by lamotrigine. J Child Neurol. 2006; 21(4): 357. author reply -8. DOI: 10.1177/08830738060210041301
- 4Braga MF, Aroniadou-Anderjaska V, Post RM, Li H. Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. Neuropharmacology. 2002; 42(4): 522–9. DOI: 10.1016/S0028-3908(01)00198-8
- 5Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92(4): 414–7. DOI: 10.1038/clpt.2012.96
- 6Rissardo JP, Fornari Caprara AL. Lamotrigine-Associated Movement Disorder: A Literature Review. Neurol India. 2021; 69(6): 1524–38. DOI: 10.4103/0028-3886.333440
- 7Zaatreh M, Tennison M, D’Cruz O, Beach RL. Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? Seizure. 2001; 10(8): 596–9. DOI: 10.1053/seiz.2001.0555
- 8Saenz-Farret M, Tijssen MAJ, Eliashiv D, Fisher RS, Sethi K, Fasano A. Antiseizure Drugs and Movement Disorders. CNS Drugs. 2022; 36(8): 859–76. DOI: 10.1007/s40263-022-00937-x
- 9Das KB, Harris C, Smyth DP, Cross JH. Unusual side effects of lamotrigine therapy. J Child Neurol. 2003; 18(7): 479–80. DOI: 10.1177/08830738030180070301
- 10Miller MA, Levsky ME. Choreiform dyskinesia following isolated lamotrigine overdose. Journal of Child Neurology. 2008; 23(2): 243. DOI: 10.1177/0883073807308693
- 11Monbaliu E, Himmelmann K, Lin JP, Ortibus E, Bonouvrié L, Feys H, et al. Clinical presentation and management of dyskinetic cerebral palsy. Lancet Neurol. 2017; 16(9): 741–9. DOI: 10.1016/S1474-4422(17)30252-1
- 12Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord. 1993; 8(1): 19–27. DOI: 10.1002/mds.870080104
- 13Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther. 2003; 25(10): 2506–38. DOI: 10.1016/S0149-2918(03)80314-4
- 14Dickens D, Owen A, Alfirevic A, Giannoudis A, Davies A, Weksler B, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012; 83(6): 805–14. DOI: 10.1016/j.bcp.2011.12.032
- 15Joo EY, Tae WS, Hong SB. Regional effects of lamotrigine on cerebral glucose metabolism in idiopathic generalized epilepsy. Arch Neurol. 2006; 63(9): 1282–6. DOI: 10.1001/archneur.63.9.1282
- 16Mink JW. The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol. 2003; 60(10): 1365–8. DOI: 10.1001/archneur.60.10.1365